



Amyris Expands Production Contract with ADL BioPharma Due to Demand Growth

EMERYVILLE, Calif. June 28, 2018.- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable, fermentation-derived ingredients for Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announces that it expanded its existing production contract with Antibióticos de León (ADL Biopharma; MAB:ADL).

Amyris is disrupting markets by using the most advanced science and technology, including machine-learning and robotics to program yeast to create targeted molecules, at a lower cost and with sustainable supplies, resulting in sustainable methods of materials production. Amyris is the only company in the sector that has production capability at industrial scale, is evidenced by its clean manufacturing and commercialization of 15 products and its established supply agreements with market leaders across a range of business segments.

Amyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners. ADL Biopharma is one of the first CMOs that Amyris has used to successfully produce farnesene.

“We are pleased to grow our relationship with ADL to meet the strong demand from our customers,” said John Melo, President & CEO of Amyris. “It’s great to be able to rely on ADL to respond quickly, just as we did when we took an active ingredient in skincare from development to commercial scale in record time. Low-cost, high purity and predictability are what our customers have come to depend on Amyris for.”

“With the extension of the original collaboration signed in January, we are increasing our commitment and strengthening our relationship with one of our key customers. With this increase, not only in the amount, but also in the number of products manufactured for Amyris in ADL facilities, Amyris and ADL reinforce their mutual support commitment to a successful long-term relationship,” said Pilar de la Huerta, CEO of ADL Biopharma.



amyris

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

About ADL Biopharma

ADL Biopharma is one of the European players for the development and production of fermentation process-based projects, with a total capacity of 2,400 cubic meters, the largest fermentation facility in Southern Europe. ADL Biopharma operates in three separate and complementary business lines at the same time: manufacture of active pharmaceutical ingredients (API); development and upscaling services for third parties (CRO); and contract industrial production by fermentation processes (CMO). The company provides qualified employment to more than 250 people and its markets are mainly located in Europe and the United States. ADL Biopharma is part of ADL Bionatur Solutions, a European leader in biotech health sector focused on high value fermentation products. ADL Bionatur Solutions is quoted on the alternative Spanish stock exchange (MaB, ticket ADL). More information about the company is available at www.adlbiopharma.com/ www.adlbionatur.com